Arcus Biosciences, Inc.·4

Jun 12, 4:28 PM ET

Tang Carolyn C. 4

4 · Arcus Biosciences, Inc. · Filed Jun 12, 2026

Research Summary

AI-generated summary of this filing

Updated

Arcus (RCUS) GC Carolyn Tang Exercises Stock Options

What Happened Carolyn C. Tang, General Counsel of Arcus Biosciences (RCUS), exercised stock options on 2026-06-11. The filing reports the acquisition of 34,090 shares at an exercise price of $2.57 per share (total paid $87,748), and a matching disposition of 34,090 shares at $2.57 (reported as a derivative transaction). The transaction code reported is M (exercise or conversion of a derivative).

Key Details

  • Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely).
  • Exercise: 34,090 shares @ $2.57 = $87,748 (Acquired, code M).
  • Disposition: 34,090 shares @ $2.57 = $87,748 (Derivative — same quantity).
  • Shares owned after the transaction: not specified in the provided filing.
  • Footnotes of note:
    • F1: Includes 1,783 shares purchased 5/31/2026 via the company ESPP.
    • F2: Ownership figures include unvested portions of RSU grants.
    • F3: The option was fully vested and has been completely exercised.
  • Filing was timely (no late-report indication).

Context The paired acquisition and disposition entries generally indicate a cashless or net-share exercise (shares acquired via option exercise and immediately transferred/sold, often to cover exercise costs or taxes). Per footnote F3, the option exercised was fully vested and fully exercised. This type of insider activity is often routine and does not by itself indicate a change in the insider’s view of the company.

Insider Transaction Report

Form 4
Period: 2026-06-11
Tang Carolyn C.
General Counsel
Transactions
  • Exercise/Conversion

    Common Stock

    [F1][F2]
    2026-06-11$2.57/sh+34,090$87,748184,607 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F3]
    2026-06-11$2.57/sh34,090$87,7480 total
    Exercise: $2.57Exp: 2027-08-30Common Stock (34,090 underlying)
Footnotes (3)
  • [F1]Includes 1,783 shares purchased on May 31, 2026 through the Company's Employee Stock Purchase Plan.
  • [F2]Includes the unvested portion of the Reporting Person's RSU grants.
  • [F3]The option is fully vested and has been completely exercised.
Signature
/s/ Carolyn Tang, Attorney-in-Fact|2026-06-12

Documents

1 file
  • 4
    wk-form4_1781296090.xmlPrimary

    FORM 4